J. Clin. Med., 2022 · DOI: 10.3390/jcm11082115 · Published: April 11, 2022
This study investigates potential treatments for spinal cord ischemia (SCI), a serious complication of aortic repair surgery. Researchers explored whether pre-treating or post-treating nerve cells with a Toll-like receptor 3 (TLR3) agonist or shock wave therapy (SWT) could reduce damage after a simulated ischemic event in cultured cells. The study found that both TLR3 activation and SWT could decrease apoptosis (cell death) and pro-inflammatory cytokine expression in vitro. Specifically, pre-ischemic TLR3 activation seemed more effective, while post-ischemic SWT also showed promise. These findings suggest that TLR3 agonists and SWT might offer new treatment strategies for ischemic spinal cord injury by reducing inflammation and cell death in the spinal cord after aortic repair.
The study suggests that both TLR3 agonists and SWT could be explored as potential therapeutic strategies for mitigating spinal cord ischemia following aortic repair.
The research highlights the importance of modulating inflammation in the context of SCI and provides insights into how TLR3 activation and SWT can influence the inflammatory response.
The findings indicate that pre- and postconditioning with TLR3 agonists or SWT can offer neuroprotection by reducing neuronal apoptosis in the setting of ischemic neuronal injury.